Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851958 | 0.86 | MAPK14 (0.73) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL2850942 | 0.85 | MAPK14 (0.75) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL2842830 | 0.85 | MAPK14 (0.75) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3235614 | 0.85 | MAPK14 (0.68) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3229947 | 0.82 | MAPK14 (0.76) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3231165 | 0.82 | MAPK14 (0.76) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3230731 | 0.80 | MAPK14 (0.75) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3226498 | 0.80 | MAPK14 (0.77) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL2849082 | 0.77 | MAPK14 (0.77) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL3232081 | 0.77 | MAPK14 (0.64) | MAPK14GSK3BMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | claimed |
| EP-1894925-A1 | Imidazole compounds having an antiinflammatory effect | MERCKLE GMBH (DE) | 2008-03-05 | — | — | EP | claimed |
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2054404-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1894925-A1 | Imidazole compounds having an antiinflammatory effect | MERCKLE GMBH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008023066-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MIF, TNF, IL1B | MAPK14 2368/4885GSK3B 3289/4885MAPK13 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.